The coexistence of type 2 diabetes mellitus (T2DM) and heart failure (HF), either with reduced (HFrEF) or preserved ejection fraction (HFpEF), is frequent (30-40% of patients) and associated with a higher risk of HF hospitalization, all-cause and cardiovascular (CV) mortality. The most important causes of HF in T2DM are coronary artery disease, arterial hypertension and a direct detrimental effect of T2DM on the myocardium. T2DM is often unrecognized in HF patients, and vice versa, which emphasizes the importance of an active search for both
Introduction
The coexistence of heart failure (HF) and type 2 diabetes mellitus (T2DM) is common and has a strong impact on clinical management and prognosis. T2DM is associated with worse clinical status and increased all-cause and cardiovascular (CV) mortality in both patients with HF with reduced (HFrEF) and preserved ejection fraction (HFpEF), compared to HF patients without T2DM. 1 Conversely, HFrEF is an independent predictor of fatal and non-fatal clinical outcomes in patients with T2DM. 2, 3 The major causes of HF in T2DM include coronary artery disease (CAD) and hypertension, but also, a possible direct detrimental effect of T2DM on the myocardium. 4 This position paper provides advice and education pertinent to the clinical management of patients with T2DM and HF. The document summarizes the epidemiology and current understanding of the mechanisms underlying the intersection between T2DM and HF. It further presents contemporary treatment options for patients with established T2DM and HF, and summarizes recent evidence of HF prevention with drugs used to treat T2DM.
Epidemiology Prevalence of type 2 diabetes mellitus and heart failure in general populations
The prevalence of T2DM, which encompasses 90-95% of diabetic individuals, has globally increased from 4.7% in 1980 to 8.5% in 2014, 5 albeit diagnostic criteria have changed over that period. 6, 7 Contemporary data suggest a stable overall HF prevalence of 11.8% (range 4.7-13.3%) in the general population. 8 
Prevalence of heart failure in patients with type 2 diabetes mellitus
In the Reykjavik study in the general population, the prevalence of HF in people with T2DM was 12%. 9 In this study, HF was more common in patients with T2DM aged >70 years (i. e UKPDS 33 11 NR (severe concurrent illness excluded) ADVANCE 12, 13 NR ACCORD 14 4.3% VADT 15 NR DPP4 inhibitor trials SAVOR-TIMI 53 16, 17 13% TECOS 18 18% EXAMINE 19 28% SGLT2 inhibitor trials EMPA-REG OUTCOME 20 10% CANVAS 21 14-15% GLP-1 receptor agonist trials LEADER 22 14% ELIXA 23 22% EXSCEL 24 16%
Glucose-lowering trials
DPP4, dipeptidyl peptidase-4; GLP-1, glucagon-like peptide-1; HF, heart failure; NR, not reported; SGLT2, sodium-glucose co-transporter type 2. of men and women, respectively). In the Kaiser Permanente population, patients with T2DM aged <75 years had an approximately three-fold higher prevalence of HF compared to those without T2DM. 10 In those aged 75-84 years, T2DM was associated with a doubling of risk for HF. In these relatively old studies, HF phenotype (i.e. HFrEF or HFpEF) or biomarker status was not reported. In clinical trials of T2DM patients, the prevalence of HF at baseline has varied between approximately 10% and 30% ( Table 1) . 11 -24 marked regional differences have been observed both in Europe and in rest of the world. In studies conducted in Iceland 9 and Italy, 27 T2DM prevalence was four and three times higher, respectively, whereas in Italy, T2DM prevalence was almost doubled in HF subjects ( Table 2) . Approximately 25% of patients with HF in England 25 and Denmark 28 also had T2DM. Despite younger age and less obesity, a significantly higher prevalence of T2DM (57%) was observed in a population-based cohort of Southeast Asian HF patients compared to Caucasian patients (24%). 30 The reasons for the wide regional variation in T2DM prevalence in HF patients warrant further international studies with shared study design and standardized data collection.
In clinical trials of chronic HF patients, the prevalence of T2DM was around 30%, irrespective of HF phenotype (i.e. HFrEF and HFpEF) ( Table 3) . 31 -48 The highest prevalence of T2DM was seen in trials of acute HF (around 40%).
In registries of hospitalized HF patients in North America and Europe, the prevalence of T2DM is around 40-45%, 49 -52 and a slight increase in the prevalence was reported in North America over time. 49, 52 . In the Swedish HF Registry (68% from hospitals and 32% from primary care), T2DM was more prevalent in HF patients with CAD compared to those without (30% vs. 19%).
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Incidence of new type 2 diabetes mellitus in patients with heart failure
In patients with HF, data from observational and clinical trials demonstrate an increased risk for new-onset T2DM compared to patients without HF. In a Kaiser Permanente study, the incidence of T2DM was significantly higher in patients with than without HF (i.e. 13 .6/1000 vs. 9 .2/1000) over a 5-year follow-up. 10 In a Danish nationwide cohort study, 8% of HF patients developed T2DM over 3 years, and the severity of HF was associated with a stepwise increased risk of developing T2DM. 54 Similar incidence of T2DM was reported in clinical trials of HF patients, as demonstrated by the CHARM program, in which 7.8% of patients developed T2DM over 2.8 years. 55, 56 In the EMPHASIS-HF trial including HFrEF patients, the incidence of T2DM was 3.7% over a median follow-up of 21 months. 57 Notably, HF treatment with angiotensin-converting enzyme (ACE) inhibitors was shown to lower the incidence of T2DM in HFrEF patients; in a substudy of the SOLVD trial, 6% of patients in the enalapril arm developed T2DM over a mean . 42 .6% RELAX-AHF-2 48 47%
Trials of HFrEF
HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; T2DM, type 2 diabetes mellitus.
follow-up of 2.9 years as opposed to 22% in the placebo arm. 58 Registry data corroborate that the use of renin-angiotensin system inhibitors is associated with attenuated risk for T2DM in HF patients receiving loop diuretics. 54 Clinical trials also demonstrated that the severity of HF, as indicated by a higher New York Heart Association (NYHA) class, increases the likelihood of developing T2DM. 27, 59 Incidence of heart failure in patients with type 2 diabetes mellitus demonstrated that incident HF was observed more frequently (14.1%) than vascular events, including myocardial infarction (MI) or stroke. 60 T2DM is an independent risk factor for the development of HF. 10 In a retrospective cohort followed for up to 72 months, patients with T2DM were more likely to develop HF than patients without T2DM (incidence rate 30.9 vs. 12.4/1000 person-years, rate ratio 2.5). 61 In elderly patients with T2DM, the incidence of HF was two-fold higher compared to patients without T2DM (121 vs. 62 cases/1000 patient-years). 62 In the UKPDS 35 trial including newly diagnosed diabetic patients, HF incidence steeply increased with the severity of dysglycaemia ranging from 2.3 to 11.9/1000 person-years for patients with glycated haemoglobin (HbA 1c ) <6% and HbA 1c >10%, respectively. 63 Similarly, in observational studies (NHANES 64 and ARIC 65 ), the incidence of HF in patients with T2DM was higher than in those without T2DM, with the corresponding hazard ratios (HRs) of 1.85 and 3. 54 . Indeed, in the ARIC study, higher HbA 1c levels in T2DM patients were associated with significantly more incident HF cases than in patients with T2DM and lower HbA 1c levels. 65 The incidence of HF in T2DM patients compared to those without T2DM is even higher in patients with established CAD, in which each 1% increase in HbA 1c level was associated with a 36% increased risk for HF hospitalization. 66, 67 Patients with pre-diabetes in the ARIC study also had more HF than those without pre-diabetes. 69, 70 In the SOLVD-Prevention trial of patients with asymptomatic left ventricular systolic dysfunction, patients with T2DM were more likely to progress to symptomatic HF than those without T2DM, although the increased risk appeared to be confined to patients with HF secondary to CAD. 71 Most trials also demonstrated worse quality of life in patients with T2DM and concurrent HF (both HFrEF and HFpEF), as compared to patients without T2DM. 40, 69 Patients with T2DM and HFrEF also have shorter 6-minute walk distances and decreased peak oxygen uptake in comparison to non-diabetics. 55 (Table 4) . 26,29,51,73 -81 In Sweden, there was a moderately higher risk (HR 1.60) 53 and in the Netherlands a significantly higher risk of death (HR 3.19) 26 attributed to T2DM. Additionally, in the Rotterdam study, T2DM was associated with an excess risk for CV death (HR 3.25) that was similar to the risk of all-cause mortality. 26 Likewise, all studies of the effect of T2DM on mortality in HF outpatients have found a higher mortality risk attributable to T2DM ( Table 4) .
Concerning patients hospitalized for HF, data on the association between T2DM and in-hospital mortality are divergent. In the OPTIMIZE-HF, ADHERE and Get With the Guidelines-HF registries in the United States, T2DM was not associated with higher in-hospital mortality. 82 -85 Conversely, in the ALARM registry (six European countries, Mexico and Australia), and in the European Society of Cardiology (ESC) HF Long-Term Registry, T2DM was independently associated with a higher risk of in-hospital mortality. 51, 86 There is a suggestion from some cohorts 82,87 that short-term mortality in HF patients post-discharge may be similar or slightly lower in those with T2DM. However, with longer-term follow-up, an association between T2DM and worse outcomes in HF patients becomes evident. For example, in the EVEREST trial in which patients were followed for 9.9 months after a HF hospitalization, T2DM conferred a slightly higher mortality. 45 Also, in patients from Scotland, T2DM increased mid-to-long-term mortality following hospitalization for HF. 87 Likewise, in the ESC HF Long-Term Registry, the presence of T2DM was independently associated with increased 1-year all-cause mortality. 51, 73 Clinical trial results are somewhat conflicting regarding the risk of all-cause and CV mortality attributed to T2DM in HF patients, but most clinical trials reported an increased risk of death in patients with concurrent T2DM and HF (Table 5) . 1,31 -35,37,40,42,44,45,69,88-92 In HFrEF, five out of eight trials demonstrated an association between T2DM and increased all-cause mortality, with the reported HRs between 1.3 and 2.0 (mostly around 1.5) ( Table 5) . Also three HFrEF trials reported increased CV death, with HRs between 1.5 and 1. 8. 1,31,33 Concerning HFpEF, all trials reported increased all-cause mortality (HRs 1.5 to 1.8) and two out of four trials also reported an increased risk of CV mortality in patients with T2DM compared to patients without T2DM, with HRs 1.6 to 1.9 ( Table 5 ). In the CHARM trial, T2DM was an independent risk factor for both all-cause mortality and CV mortality even after adjustment for 32 covariates. 1 Additionally, in the same study, T2DM had a greater association with higher all-cause and CV mortality in patients with HFpEF than HFrEF.
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A recent meta-analysis of 31 registries and 12 clinical trials with 381 725 patients with acute and chronic HF, with a median follow-up of 3 years confirms that T2DM is independently associated with a higher risk of all-cause death (random-effects HR 1.28) , CV death (HR 1.34) , hospitalization (HR 1.35) , and the combined endpoint of all-cause death or hospitalization (HR 1.41) , and the observed long-term risk appears greater in patients with chronic than in those with acute HF. 
Type 2 diabetes mellitus and causes of death in patients with heart failure
In the CHARM trial, patients with T2DM and both HFrEF and HFpEF were more likely to die of all subtypes of CV death [i.e. death due to HF, sudden cardiac death (SCD), death due to MI and death due to stroke]. 1 The PARADIGM-HF study also reported that patients with T2DM and HFrEF were more likely to die of CV as well as all-cause mortality compared with patients without T2DM. 69 In the BEST trial, T2DM was an independent risk factor for death from pump failure. 94 Aside from CV death, results from the Emerging Risk Factors Collaboration, including 820 900 people, demonstrate that T2DM is independently associated with increased risk of death from several cancers (i.e. liver, pancreas, ovary, colorectum, lung, bladder, and breast), renal and liver disease, pneumonia and other infectious diseases, mental and nervous system disorders, non-hepatic digestive diseases, external causes, and chronic obstructive pulmonary disease. 95 The study found that a 50-year-old with T2DM died, on average, 6 years earlier than an individual without T2DM, with about 40% of the difference in survival attributable to excess non-vascular deaths. 95 .
Is the higher risk of type 2 diabetes mellitus only seen in heart failure secondary to coronary artery disease?
Whether or not the increased risk of mortality with T2DM in HF patients is seen in both those of ischaemic and non-ischaemic aetiology is uncertain. The majority of the available data suggests that T2DM is associated with higher risk of mortality in both patients of ischaemic and non-ischaemic aetiology (Table 6) . 29, 88, 94, 96 -99 In a population-based Danish study, which followed patients for 6.8 years, patients with T2DM and HF had higher mortality whether or not they had CAD. 96 The higher risk appeared early and persisted throughout follow-up. In the CHARM trial, patients with both HFrEF and HFpEF had higher mortality attributed to T2DM whether or not they had CAD. 1 In the DIAMOND trial, T2DM was associated with a higher risk of mortality in both ischaemic and non-ischaemic HF. 100 These consistent findings conflict with two smaller population-based studies in the United States 29 and France 97 and one Spanish single-centre study 101 of patients hospitalized with HF, which suggested that diabetes was only associated with higher mortality in those with non-ischaemic aetiology. In three early clinical trials (SOLVD, 98 BEST, 94 and DIG 102 ) the risk appeared to be confined to those with an ischaemic aetiology. Is the higher risk of mortality with type 2 diabetes mellitus and heart failure seen in both women and men?
An early report from the Framingham study reported that the mortality risk related to T2DM was confined to women and not to men. 103 In two population-based studies from Scotland and Sweden, the increased mortality risk of T2DM was seen in both women and men, but the effect was slightly greater in women. 87, 96 Likewise, in the recent ESC HF Long-Term Registry and in the CHARM trial, T2DM was a risk factor for mortality in both men and women.
1,73
Does glycated haemoglobin predict mortality in patients with heart failure and type 2 diabetes mellitus?
In the CHARM trial, high HbA 1c was associated with increased all-cause and CV mortality in patients with T2DM and both HFrEF and HFpEF. 104 A 1% increase in HbA 1c was associated with an increased HR of 1.1 for CV mortality. 104 In patients from a US study of HF clinics, a U-shaped relationship with regard to increased all-cause mortality was found. 71 Patients with either very low . or very high HbA 1c were at greatest risk. A similar U-shaped curve was found in a single-centre study from Scotland. 105 In one single-centre observational study of 123 young patients with advanced HF and T2DM, patients with a HbA 1c of <7% had higher rates of all-cause mortality. 106 In the GISSI-HF study, including 6935 chronic HF patients, the presence of T2DM and higher HbA 1c levels was an independent predictor of all-cause mortality (HRs 1.43 and 1.21, respectively) and the composite outcome of mortality and CV hospitalization (HRs 1.21 and 1.14, respectively).
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In summary, high HbA 1c levels in T2DM and HF are consistently associated with higher mortality. Conversely, low HbA 1c levels can be associated with good outcomes (at least in a clinical trial cohort), but can be associated with worse outcomes (in population-based studies and those with very advanced HF).
Pre-diabetes and undiagnosed type 2 diabetes mellitus and risk of mortality in heart failure
In the PARADIGM-HF trial, patients with pre-diabetes were at increased risk of mortality. 69 Patients with undiagnosed T2DM were also at higher risk of mortality than subjects without T2DM, but the risk was not as high as in patients with previously known T2DM . In CHARM, pre-diabetes and undiagnosed T2DM were both associated with greater rates of HF hospitalization, CV and all-cause mortality than those without T2DM. 108 However, not all studies have reported an increased mortality risk with pre-diabetes. In a study of 970 non-diabetic patients with HF, an increased 1-year mortality risk was found only in patients with HbA 1c >6.7% and reduced left ventricular ejection fraction (≤45%), but not in those with HFpEF. 109 Also, in the GISSI-HF study of unselected HF patients, pre-diabetes was not an independent predictor of increased mortality. 107 The reasons behind these discrepancies might be attributed to differences in patient characteristics and warrant further assessment.
Type 2 diabetes mellitus and risk for heart failure hospitalization
Several clinical trials documented that patients with T2DM and HFrEF were more likely than patients without T2DM to be hospitalized for HF. 1, 37, 69, 70, 94 In the CHARM trial, rates of hospitalization for HF in patients with T2DM were greater for . 
Readmission after a hospitalization for heart failure
Registry data indicate that patients with T2DM had more all-cause rehospitalizations than those without T2DM. 79, 82, 110 In a population-based study in Scotland, T2DM was a predictor of readmission for HF (with the increased risk greatest in younger women). 87 In the ESC HF Long-Term Registry, T2DM was independently associated with rehospitalization for HF. 51 Likewise, in the EVEREST trial, T2DM was associated with greater rates of HF rehospitalization (HR 1.19) . 45 In addition, as demonstrate by the OPTIMIZE-HF and Get With The Guidelines-HF registries in the United States, patients with HF and T2DM experience slightly longer hospitalizations than patients without T2DM. 82 
-84
Type 2 diabetes mellitus, myocardial infarction and stroke in patients with heart failure
The only trial to investigate the association between T2DM and risk of MI and stroke in HF patients was the CHARM trial demonstrating that the presence of T2DM increased the risk for MI and stroke irrespective of HF phenotype (i.e. HFrEF or HFpEF).
1
Risk for heart failure hospitalization in patients with type 2 diabetes mellitus without a previous history of heart failure
In the ARIC registry, representing a cohort of 14 079 people in the community without known HF, T2DM was the most powerful risk factor for incident HF hospitalization. 110 In a large meta-analysis of patients with T2DM but without HF, predictors of incident HF included insulin use, HbA 1c and fasting glucose.
111
Mortality in type 2 diabetes mellitus patients with heart failure
In the CV outcomes trials of new therapies for T2DM, the development of HF is associated with markedly higher mortality (especially in RECORD 112 and SAVOR-TIMI 53 16 ). Patients with T2DM who developed HF had a 10 to 12 times greater mortality than those who did not develop HF. 3, 113 In addition, they are also at a 2.45-fold greater risk of CV death compared with patients with T2DM but without HF.
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Unrecognized heart failure in patients with type 2 diabetes mellitus and unrecognized type 2 diabetes mellitus in patients with heart failure Observational evidence indicates that a significant proportion of patients aged ≥60 years (27.7%) may have unrecognized HF (22.9% and 4.8%, HFpEF and HFrEF, respectively) based on the ESC diagnostic criteria. 115, 116 On the other hand, pre-diabetes and undiagnosed T2DM are common in patients with HF. In the PARADIGM-HF trial, 13% of patients with HFrEF had undiagnosed T2DM and 25% had pre-diabetes. 69 Likewise, 11% of 'non-T2DM' patients with HFrEF in the RESOLVD trial had undiagnosed T2DM. 117 In the CHARM study, undiagnosed T2DM was common in both HFrEF and HFpEF. 108 In the ESC HF Long-Term Registry, even higher proportion of HF patients (19.1%) had undiagnosed T2DM. 73 Considering prognostic implications of concurrent T2DM and HF, these findings stress the importance of developing screening strategies for unrecognized HF among T2DM patients and vice versa. HF that may require further assessment (e.g. echocardiography).
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Such a strategy may be used to prevent complications and possibly improve outcomes, particularly in subjects with HFrEF.
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Conversely, since undiagnosed T2DM is common among patients with HF, it is prudent to screen patients without known T2DM in accordance with current recommendations using the 8 h fasting plasma glucose, 2 h glucose tolerance test or HbA 1c levels (equally appropriate).
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Pathophysiological aspects of myocardial dysfunction in type 2 diabetes mellitus
The most common co-existing conditions that cause HF in patients with T2DM are CAD and hypertension. It has also been hypothesized that T2DM-related processes can cause HF by directly affecting the structure and function of the heart. 4 The major drivers of myocardial dysfunction in T2DM are insulin resistance/hyperinsulinaemia and impaired glucose tolerance, which may be effective years or even decades before overt T2DM develops. 121 Their detrimental effect is associated with numerous metabolic abnormalities such as advanced glycosylation end products (AGEs) deposition, lipotoxicity and microvascular rarefication. 4 Harmful interrelations between these pathophysiologic mechanisms may exert a potentiating effect, leading to several maladaptive responses and resulting in myocyte alteration. 4 Insulin resistance leads to increased free fatty acid release and is linked with HF-related neuroendocrine dysregulation. 122 It is also an important aetiological factor in the development of left ventricular hypertrophy, 123 as confirmed in the Framingham study, where left ventricular mass was significantly higher in female patients with T2DM compared to patients without T2DM. 124 Hyperglycaemia also exerts extensive influences on CV changes in T2DM, and can directly cause cardiomyocyte contractile dysfunction, mitochondrial network fragmentation and an increase in protein kinase C activity.
125 -127 Also, it causes activation of reactive oxygen species and the deposition of AGEs in both endothelial and smooth muscle cells, which predisposes to concentric left ventricular remodelling and raises left ventricular diastolic stiffness. 125, 126 High myocardial free fatty acid uptake results in the accumulation of triglyceride in the myocardium (i.e. lipotoxicity). Cardiac steatosis, confirmed by proton magnetic resonance spectroscopy, is the clinical equivalent of high myocardial triglyceride content and may present as left ventricular diastolic dysfunction.
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Diabetic cardiomyopathy
In 1954, Lundbaek was the first to propose the existence of a specific diabetic heart muscle disease without involvement of CAD or hypertension. 129 Two decades later, Rubler et al. 130 described diabetic-related post-mortem findings in four patients with T2DM, glomerulosclerosis and HFrEF with normal epicardial coronary arteries. There is no definition of diabetic cardiomyopathy, which makes studies of epidemiology, pathophysiology, natural history and associated clinical outcomes challenging. The most commonly accepted definition refers to a myocardial dysfunction which occurs in the absence of all other CV disease.
120,131
Phenotypes of type 2 diabetes mellitus-related cardiomyopathy Left ventricular diastolic dysfunction and heart failure with preserved ejection fraction in type 2 diabetes mellitus Left ventricular diastolic dysfunction can be detected in 75% of T2DM patients and develops early in T2DM course, as confirmed by demographic characteristics of these patients, including younger age, normal blood pressure and optimal T2DM control.
132,133
Furthermore, the degree of glucose dysregulation correlates with left ventricular diastolic dysfunction severity, 134 and with increased risk of incident HF and CV mortality in T2DM.
135 -137 Almost half of HF patients with T2DM have HFpEF, which is more frequent in older, hypertensive and female patients with T2DM and is difficult to diagnose because the symptoms are often mild, appear upon physical activity, and could be frequently misdiagnosed as chronic obstructive pulmonary disease. 89 HFpEF is usually associated with mild T2DM complications in the early stages of T2DM, whilst HFrEF is associated with more severe T2DM complications. 138 This suggests that severity and duration of hyperglycaemia are important for the development of left ventricular dysfunction.
Heart failure with reduced ejection fraction in type 2 diabetes mellitus
The major cause of HFrEF in T2DM is CAD. T2DM is associated with a two-fold higher risk of CAD and ischaemic stroke, and a two-to four-fold higher CAD-and stroke-related mortality.
139 -141 CAD in T2DM is usually diffuse, multi-vessel and may lead to silent MI.
Treatment of heart failure in patients with type 2 diabetes mellitus
There are no specific constraints to HF treatment in T2DM patients as recommended by the 2016 ESC guidelines for the management of HF. 116 In clinical trials, all pharmacological and device therapies for HF were similarly effective whether or not patients had T2DM. Thus far, there were no clinical trials of HF treatment that included only patients with T2DM, and available evidence is derived from subanalyses of mixed populations. However, several HF drugs may exert metabolic effects that should be taken into account in T2DM patients.
Pharmacological therapy
Angiotensin-converting enzyme inhibitors
The ESC/EASD guidelines on diabetes, pre-diabetes, and CV diseases recommend angiotensin-converting enzyme (ACE)-inhibitors . in patients with HFrEF and T2DM, as they have been shown to improve symptoms and reduce morbidity and mortality. 116 The effectiveness of ACE-inhibitors in patients with both T2DM and HF, or post-MI left ventricular systolic dysfunction was examined in a large meta-analysis of seven randomized clinical trials (RCTs).
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For the endpoint of all-cause mortality, ACE-inhibitors had a similar treatment benefit in subjects with and without T2DM (HR 0.84 and 0.85, respectively).
The only large ACE-inhibitor trial in HFrEF to provide detailed information on patients with T2DM was the ATLAS, which compared low-dose (2.5-5.0 mg daily) to high-dose (32.5-35.0 mg daily) lisinopril. 143, 144 The greater relative benefit for the composite primary endpoint (all-cause mortality or HF hospitalization) of high-dose lisinopril was similar in patients with and without T2DM. However, because patients with T2DM were at greater risk, the absolute benefit of high-dose lisinopril was larger in patients with T2DM. 144 The occurrence of adverse effects with high-dose lisinopril was similar in those with and without T2DM with respect to hypotension/dizziness (35% vs. 32%), renal dysfunction/hyperkalaemia (29% vs. 22%) and cough (12% vs. 10%). 144 
Angiotensin receptor blockers
In the CHARM trial, a significant reduction in CV death, HF hospitalization and all-cause mortality was achieved with candesartan in patients with HF and HFrEF, irrespectively of T2DM.
1 Also, in the Val-HeFT, valsartan treatment led to a significant relative risk reduction in the co-primary composite endpoint (death or HF morbidity-mainly HF hospitalization) regardless of T2DM. 145 A subsequent trial (HEAAL 146 ) showed that 150 mg daily of losartan was superior to 50 mg daily in reducing the risk of death or HF hospitalization, supporting the similar findings of the ATLAS trial with the ACE-inhibitor lisinopril. The treatment effect was again not different in the subgroup of patients with T2DM compared to those without T2DM (HR 0.96; interaction P=0. 35 ).
There is little information about the tolerability of angiotensin receptor blockers (ARBs) in T2DM. In the overall CHARM program, patients with T2DM had double the risk of developing hyperkalaemia on candesartan compared to those without T2DM.
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T2DM confers a higher risk of diabetic nephropathy and chronic kidney disease. 148 Specifically, diabetic nephropathy is characterized by increased renal sodium retention 149, 150 and a higher risk of hyperkalaemia. 151 This caveat deserves consideration when ACE-inhibitors or ARBs are administered to diabetic patients, as these drugs may interfere with renal potassium excretion. Hence, monitoring of serum electrolytes and creatinine is recommended when starting or escalating the dose of ACE-inhibitors or ARBs.
Beta-blockers
Subgroup analyses of large HF trials show that beta-blockers reduce mortality and hospitalization and improve symptoms in moderate to severe HF, irrespectively of T2DM. 37, 152, 153 Beta-blockers recommended in HF and T2DM include metoprolol succinate (MERIT-HF), 37 bisoprolol (CIBIS II) 152 and carvedilol (COPERNI-CUS and COMET). 154, 155 The MERIT-HF trial reported similar efficacy and safety of metoprolol succinate in patients with and without T2DM. 37 Adverse events were more often observed in T2DM patients, but were less likely to occur if those patients were treated with metoprolol succinate than with placebo. In a meta-analysis of six trials, beta-blocker therapy reduced all-cause mortality in patients with T2DM (HR 0.84) similarly to those without T2DM (HR 0.72). 156 An analysis of three trials (CIBIS II, MERIT-HF and COPERNICUS) reported a relative risk reduction for mortality of 0.77 in patients with T2DM and 0.65 in patients without T2DM. 142 A third meta-analysis that focused on seven trials using carvedilol, including a post-MI trial, revealed a similar, significant reduction in the risk for mortality with carvedilol in patients with and without T2DM (28% and 37%, respectively, interaction P=0.25). 157 Hypoglycaemia is a concern in patients with T2DM treated with insulin or sulfonylureas. Theoretically, beta-blockers could alter awareness of hypoglycaemia by decreasing palpitations and tremor and prolong recovery from hypoglycaemia by blocking 2 receptors, which partly control glucose production in the liver. However, among patients with T2DM in MERIT-HF only three (0.6%) in the placebo group and four (0.8%) in the metoprolol succinate group had an adverse event related to hypoglycaemia (in each case in patients taking insulin). 37 In summary, beta-blockers in patients with T2DM and HF lead to significant improvements in morbidity and mortality that are consistent with results in patients without T2DM. These treatment benefits of beta-blockers in diabetic patients far outweigh the theoretical risks related to hypoglycaemia and minor changes in HbA 1c and serum lipids. These benefits strongly support beta-blocker treatment in patients with concurrent T2DM and HF.
Mineralocorticoid receptor antagonists
The mortality benefit of spironolactone in the RALES trial and eplerenone in the EMPHASIS-HF trial was consistent in T2DM and non-T2DM patients with HFrEF. 158, 159 Importantly, eplerenone seems to have no effect on new-onset T2DM in patients with HF, suggesting a neutral metabolic profile. 160 Caution is necessary when these medications are used in patients with impaired renal function and in those with serum potassium levels of ≥5.0 mmol/L. Monitoring of kidney function and potassium is mandatory since nephropathy is frequent in T2DM. Addition of an ARB (or renin inhibitor) to a combination of ACE-inhibitor and mineralocorticoid receptor antagonists is prohibited because of the increased risk of renal dysfunction and hyperkalaemia and the lack of additional benefit.
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Sacubitril/valsartan
In the PARADIGM-HF trial, sacubitril/valsartan was superior to the ACE-inhibitor enalapril in reducing the risks of death and HF hospitalization (primary endpoint) in patients with HFrEF. 31 A T2DM subgroup analysis has shown that the effect of sacubitril/valsartan compared with enalapril for the primary endpoint was similar in patients with and without T2DM (HR 0.83 and 0.77; respectively, interaction P=0. 40) . 69 In the post hoc analysis, treatment with sacubitril/valsartan was associated with a greater HbA 1c reduction and . 
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Nitrates and hydralazine
The A-HeFT trial examined the efficacy for the reduction in all-cause mortality, hospitalization and quality of life of a fixed dose combination of isosorbide dinitrate and hydralazine hydrochloride in African Americans with HF. 163 A very large proportion (41%) of patients in the study had T2DM. The treatment effect on mortality was similar in patients with and without T2DM (HRs 0.56 and 0.59, respectively).
Ivabradine
In a large trial involving 6558 patients with HF (30% with T2DM), ivabradine demonstrated a significant reduction in the composite endpoint of CV death or HF hospitalization, with no difference between T2DM and non-T2DM patients (HRs 0.81 and 0.83, respectively).
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Diuretics
Diuretics are usually required to treat the symptoms and signs of fluid overload in patients with HF. There are no clinical trials examining their efficacy in patients with both T2DM and HF. Theoretically thiazide diuretics can lead to increased insulin resistance and subsequent worsening of glycaemic control.
Devices and surgery Implantable cardioverter-defibrillators
In addition to a higher risk of death due to worsening HF, patients with T2DM and HF are at increased risk of malignant ventricular arrhythmias and SCD. In the CHARM trial, patients with T2DM experienced a significantly higher rate of SCD compared to patients without T2DM (40 vs. 25.9 events/1000 patient-years of follow-up), and the increased risk of SCD was observed irrespective of HF phenotype (i.e. HFrEF and HFpEF).
1 Observational data also demonstrate an increased risk of SCD in the presence of T2DM in HF of both ischaemic and non-ischaemic aetiology. 75 Device therapies, implantable cardioverter-defibrillator (ICD) and cardiac resynchronization therapy with ICD (CRT-D) offer a possibility to reduce overall mortality with effective prevention of SCD, and data from clinical trials support this notion in patients with and without T2DM.
The SCD-HeFT trial included patients with both non-ischaemic and ischaemic HFrEF who were randomized to placebo, amiodarone, or an ICD. 165 The study included approximately 30% of patients with T2DM in every treatment arm. ICD treatment led to a significant relative risk reduction in death and in subgroup analysis, there were no interactions with T2DM. The HRs for the primary endpoint of all-cause mortality in the ICD group were 0.95 for patients with T2DM and 0.67 for those without T2DM and in the amiodarone group 1.2 for patients with T2DM, and 1.0 for those without T2DM. In the DANISH trial, patients with non-ischaemic cardiomyopathies were randomized to ICD and optimal medical therapy or optimal medical therapy alone. 166 Approximately 19% of patients had T2DM. In pre-specified subgroup analysis, there was no significant difference in treatment effect in patients with and without T2DM (HRs 0.92 and 0.85, respectively, interaction P=0.60).
Cardiac resynchronization therapy
The effectiveness of CRT to reduce the risk of all-cause death and HF hospitalization was evaluated in two clinical trials (COMPANION 167 and CARE-HF 168 ) that randomized patients with moderate to severely symptomatic HF (NYHA class III or IV) to either optimal medical therapy or optimal medical therapy plus CRT. Additionally, two trials (MADIT-CRT 169 and RAFT 170 ), randomized patients with mild to moderate HF symptoms to optimal medical therapy plus ICD, or optimal medical therapy plus CRT-D, for the primary endpoint (death or HF hospitalization). In relation to T2DM status, both COMPANION (41% of T2DM patients), and CARE-HF (29% of T2DM patients) demonstrated similar effectiveness of CRT for the reduction in mortality and HF hospitalization.
171,172
In MADIT-CRT, CRT-D treatment, compared with optimal medical therapy plus ICD, led to a similar reduction in the risk of all-cause death or HF hospitalization in patients with and without T2DM (adjusted HRs 0.56 and 0.67, respectively). 169, 173 Also, subgroup analysis of the RAFT trial showed that the benefit of CRT-D was similar in patients with and without T2DM. 170 Patients with T2DM did not experience a higher rate of complications related to device implantation, including infection. 170 There were similar CRT-related improvements in left ventricular volumes and ejection fraction in those with and without T2DM.
Coronary artery bypass grafting
Coronary artery disease is the leading cause of premature mortality in patients with T2DM, which stresses the importance of an early detection (e.g. stress echocardiography, coronary angiography) based on the estimated CV risk, and a timely treatment of CAD.
174,175
The STICH trial addressed the broader role of surgical revascularization in patients with HFrEF and less severe CAD. 176 Patients suitable for surgery were randomized to coronary artery bypass graft (CABG) plus medical therapy or medical therapy alone. In the subanalysis of the STICH trial, there was no significant difference between patients with (40%) and without T2DM with respect to the primary outcome of all-cause mortality. 177 This trial therefore extends the indication for CABG to 'STICH-like' patients with twoor three-vessel CAD, including a left anterior descending stenosis, who are otherwise suitable for surgery. The benefits are similar whether or not a patient has T2DM.
Cardiac transplantation
Cardiac transplantation in T2DM with macrovascular complications and end-stage HF may impose several challenging issues, including renal dysfunction, peripheral vascular disease, increased . risk of infection and the need for prednisolone-based immunosuppression. T2DM was an independent risk factor for reduced 10-year survival in a large registry of 22 385 transplant patients.
178
However, with modern immunosuppression regimens allowing more rapid tapering of steroid doses and steroid-free immunosuppression, cardiac transplantation in T2DM (in the absence of major T2DM complications) should be considered on a case-by-case basis.
Exercise prescription
Recently, a single large trial (HF-ACTION 34 ) investigated the effects of exercise training in patients with mild to moderately severe HF symptoms. In an adjusted analysis, exercise training led to an 11% (P=0.03) reduction in the primary composite outcome of all-cause mortality or all-cause hospitalization. The trial enrolled 32% of patients with T2DM and there was no interaction between T2DM status and the effect of exercise on clinical outcomes.
Type 2 antidiabetic drugs and the risk of heart failure Drugs that increase heart failure hospitalizations
Over the last 15 years there has been concern that some of T2DM drugs might increase the risk for HF (Table 7) . 16 ,17,179 -182 Drugs that are now known to increase the risk for HF are thiazolidinediones (TZDs) and a dipeptidyl peptidase-4 (DPP4) inhibitor, saxagliptin. 16, 17 In the RECORD 112 and the PROactive trials, 183 patients randomized to TZDs, rosiglitazone and pioglitazone, respectively, had more HF events than those on placebo. In the SAVOR-TIMI 53 trial (saxagliptin vs. placebo), saxagliptin significantly increased the risk for HF hospitalizations (HR 1.27, P=0.007). 16 Patients at greatest risk were those with a history of HF, an estimated glomerular filtration rate (eGFR) ≤60 mL/min, or elevated baseline levels of N-terminal pro B-type natriuretic peptide (NT-proBNP). 16 In both RECORD and SAVOR-TIMI trials, patients who developed HF had a high rate of subsequent death. On that basis, pioglitazone, rosiglitazone and saxagliptin are contraindicated in patients with HF or at risk of HF.
Not all DPP4 inhibitors are associated with higher rates of HF ( Table 8) . 16 -24,184-186 In the EXAMINE trial of alogliptin vs. placebo in patients who had had an acute coronary syndrome, there was not a statistically significant increase in the risk of HF hospitalizations in patients randomized to alogliptin. 19, 184 Likewise, sitagliptin in the TECOS trial had no signal of excess rates of HF. No large RCTs. Liraglutide -two small RCTs reported no effect on (i) LV function, 180 (ii) hierarchical composite of death/HF hospitalization/BNP change. 181 Benefit/risk ratio unknown.
Sulphonylureas
No RCTs in HF. Data equivocal. Some observational data suggest an increased mortality risk with sulphonylureas compared with metformin. 179, 182 Insulin No RCTs in HF.
In observational studies in HF, insulin was associated with higher mortality rates than metformin. 179 Benefit/risk ratio unknown.
DPP4 inhibitors
No RCTs in HF (saxagliptin contraindicated in HF 16, 17 ). Benefit/risk ratio unknown.
BNP, B-type natriuretic peptide; DPP4, dipeptidyl peptidase-4; GLP-1, glucagon-like peptide-1; HF, heart failure; LV, left ventricular; RCT, randomized clinical trial; SGLT2, sodium-glucose co-transporter type 2; T2DM, type 2 diabetes mellitus.
Drugs that might increase the risk for heart failure
Over many years there has been suspicion that insulin, which causes sodium and water retention, may increase the risk for the development of HF. In large observational studies, insulin is associated with higher mortality rates than metformin. 2 There have been similar concerns with sulphonylureas which, as insulin secretagogues, have also been associated with higher death rates than metformin. 2 These studies, although large, are non-randomized and therefore inconclusive. In the only RCT of insulin vs. placebo [ORIGIN, 12 537 people with CV risk factors plus impaired fasting glucose, impaired glucose tolerance, or T2DM (i.e. not in patients with HF)], insulin was not associated with higher rates of HF hospitalization than placebo. 187 Remarkably, despite the use of insulin and sulphonylureas for decades, there are no other placebo-controlled randomized trials.
. Currently, sulphonylureas and insulin could be used in T2DM patients with HF (usually as a second-or third-line treatment), although their safety in HF is still inconclusive.
Antidiabetic drugs that might be safe in heart failure
It has been proposed that metformin might be safe and efficacious in patients with T2DM and HF. This was based on large observational studies where metformin was associated with lower mortality and HF hospitalization rates than other T2DM drugs (primarily insulin and sulphonylureas). 2 There are no RCTs of metformin in patients with T2DM and HF. Whether or not metformin is efficacious or safe is inconclusive. Previous concerns that metformin may cause metabolic acidosis are no longer justified. 2 Accordingly, metformin could be recommended as first-line treatment for patients with T2DM and HF who have preserved or moderately reduced renal function (i.e. eGFR >30 mL/min).
Glucagon-like peptide 1 (GLP-1) receptor agonists have been the subject of many large placebo-controlled trials in patients with T2DM and CV disease or at high risk of CV disease ( Table 8) . 22 -24,186 In these trials, GLP-1 receptor agonists had a neutral effect on the risk for HF hospitalization. Similarly, no signal for a higher risk for HF hospitalization was seen with acarbose (vs. placebo) in patients with insulin resistance and CAD. 188 Bromocriptine has not been studied with respect to its effect on HF outcomes.
Prevention of heart failure by type 2 antidiabetic drugs
A significant breakthrough in contemporary cardiology was the finding that some T2DM drugs are associated with a lower risk of HF hospitalization in patients with CV disease or at high risk of CV disease ( Table 8) . Two large RCTs that assessed CV safety of the sodium-glucose co-transporter type 2 (SGLT2) inhibitors, empagliflozin and canagliflozin, have shown a significant reduction in HF hospitalization with both drugs. 20, 189 The primary outcome in both trials was the three-point major adverse CV event (i.e. CV death, non-fatal MI or non-fatal stroke) and HF hospitalization was a secondary outcome. In the EMPA-REG OUTCOME trial (n=7020), including patients with T2DM, established CV disease and eGFR >30 mL/min/1.73 m 2 , there was a major reduction in HF hospitalization (HR 0.65) with empagliflozin compared with placebo. 20 The observed beneficial effect of empagliflozin became evident early (i.e. 2-3 months of treatment) and was observed across a range of pre-specified subgroups, including patients with (10%) and without investigator-reported HF at baseline, that had a similar reduction in HF hospitalizations with empagliflozin compared with placebo. No echocardiograms or natriuretic peptide measurements are available from this trial, so the detail of the beneficial effect on HF hospitalization is not available. Patients hospitalized for HF during the study had a high mortality, which was lower in patients receiving empagliflozin than placebo (13.5% vs. 24 .2%). 20 In the CANVAS trial, patients with T2DM (n=10 143) either with established CV disease or at high risk of CV disease, randomized to 24 Exenatide Placebo No effect on HF hospitalization SGLT2 inhibitors EMPA-REG OUTCOME 20 Empagliflozin Placebo Reduced HF hospitalization CANVAS 21 Canagliflozin Placebo Reduced HF hospitalization DPP4, dipeptidyl peptidase-4; GLP-1, glucagon-like peptide-1; HF, heart failure, SGLT2, sodium-glucose co-transporter type 2. canagliflozin or placebo had a significantly lower risk of HF hospitalization (HR 0.67). 21, 189 Empagliflozin in EMPA-REG OUTCOME, but not canagliflozin in CANVAS, reduced all-cause and CV mortality as well as HF hospitalization. In the EMPA-REG OUTCOME trial, the only major adverse event was an increased risk of genital tract infections, which were treatable, and infrequently recurred. 20 In the CANVAS trial, treatment with canagliflozin was associated with a significantly higher risk of lower-limb amputations (6.3 vs. 3.4 per 1000 patient-years; HR 1.97) and possibly a higher risk of fractures compared with placebo. 21 Large RCTs of other new T2DM drugs have not shown a reduction in incident HF ( Table 8) .
Treatment of heart failure with type 2 antidiabetic drugs Randomized clinical trials with SGLT2 inhibitors
While two drugs (i.e. empagliflozin and canagliflozin) have a favourable effect on HF hospitalization, no T2DM drug has yet been investigated as a treatment for HF. In 2017, three large RCTs with SGLT2 inhibitors (i.e. empagliflozin and dapagliflozin) have started, which will enrol HF patients either with or without T2DM (i.e. T2DM is not a mandatory inclusion criteria). Two trials will assess safety and efficacy of empagliflozin vs. placebo on top of guideline-based medical therapy for the reduction in primary outcome (CV death or HF hospitalization) both in patients with HFrEF (EMPEROR-Reduced, NCT03057977) and HFpEF (EMPEROR-Preserved, NCT03057951) ( Table 9) . Among secondary outcomes, the two trials will assess all-cause mortality, and renal effects of empagliflozin vs. placebo in patients with HF. The third trial (Dapa-HF, NCT03036124) will assess safety and efficacy of dapagliflozin vs. placebo for the reduction in CV death or HF hospitalization (or urgent HF visit) in patients with HFrEF. Secondary outcomes will include all-cause mortality and effects on . In addition, a number of ongoing smaller RCTs are assessing the effect of SGLT2 inhibitors on CV outcomes, including various aspects of HF in patients with and without T2DM, as summarized in Table 9 .
Randomized clinical trials with GLP-1 receptor agonists
In the LIVE trial, in patients with stable HFrEF, with and without T2DM, there were no significant changes in left ventricular ejection fraction between patients randomized on liraglutide or placebo. 180 However, there was a significant increase in heart rate (P<0.0001) and more serious cardiac adverse events with liraglutide (P=0.04). In a placebo-controlled FIGHT trial, of patients with HFrEF, with and without T2DM (41%), liraglutide was not associated with an improvement in the composite primary endpoint of death, rehospitalization and NT-proBNP change.
181
Pre-specified subgroup analyses in patients with T2DM did not reveal any significant between-group differences. A small randomized, placebo-controlled trial of albiglutide in HFrEF showed no effect on left ventricular function and 6-minute walk distance.
190
These observations have raised some concern regarding the safety of liraglutide in HFrEF patients that warrants further research.
Conclusions
Type 2 diabetes mellitus and HF are both common and frequently co-exist. The causes of HF in T2DM are numerous, but CAD and hypertension are likely the most important contributors to concurrent T2DM and HF, whereas a direct effect of T2DM on the myocardium (e.g. 'diabetic cardiomyopathy') might also play a role. Evidence from recent large-scale clinical trials and registries 
Empagliflozin
EMPEROR-Reduced (NCT03057977)
Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Reduced Ejection Fraction
• Study population: HFrEF, with and without T2DM.
• Estimated enrolment: n=2850.
• Treatment: empagliflozin vs. placebo on top of guideline-based medical therapy.
• Primary outcome: CV death or HF hospitalization (time frame: up to 38 months). EMPEROR-Preserved (NCT03057951) Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Preserved Ejection Fraction
• Study population: HFpEF, with and without T2DM.
• Estimated enrolment: n=4126.
• Primary outcome: CV death or HF hospitalization (time frame: up to 38 months). Empire HF (NCT03198585) Empagliflozin in Heart Failure Patients With Reduced Ejection Fraction
• Estimated enrolment: n=189.
• Primary outcome: change in plasma concentrations of NT-proBNP (time frame: 90 days) as a measure of treatment impact on HF.
EMMY (NCT03087773)
Impact of Empagliflozin on Cardiac Function and Biomarkers of Heart Failure in Patients With Acute Myocardial Infarction
• Study population: patients with acute MI with and without T2DM.
• Estimated enrolment: n=476.
• Treatment: empagliflozin vs. placebo.
• Primary outcome: change in plasma concentrations of NT-proBNP (time frame: 26 weeks) as a measure of treatment impact on HF.
RECEDE-CHF (NCT03226457) SGLT2 Inhibition in Combination With Diuretics in Heart Failure
• Study population: HFrEF with T2DM.
• Estimated enrolment: n=34.
• Primary outcome: the effect on the change in urine output from baseline (time frame: 6 weeks).
Canagliflozin (NCT02920918)
Treatment of Diabetes in Patients With Systolic Heart Failure
• Estimated enrolment: n=88.
• Treatment: canagliflozin vs. sitagliptin.
• Primary outcome: change in aerobic exercise capacity and ventilator efficiency (time frame: baseline and 12 weeks). • Treatment: dapagliflozin vs. placebo.
• Primary outcome: CV death or hospitalization for HF, or an urgent HF visit (time frame: from randomization up to approximately 3 years).
DEFINE-HF (NCT02653482)
Dapagliflozin Effect on Symptoms and Biomarkers in Diabetic Patients With Heart Failure
• Estimated enrolment: n=250.
• Treatment: dapagliflozin vs. placebo.
• Primary outcome: change in plasma concentrations of NT-proBNP (time frame: 12 weeks) as a measure of treatment impact on HF. 
PRESERVED-HF (NCT03030235) Dapagliflozin Effect on Symptoms and Biomarkers in patients HFpEF
• Study population: HFpEF with T2DM or pre-diabetes.
• Estimated enrolment: n=320.
• Primary outcome: change in plasma concentrations of NT-proBNP (time frame: baseline to week 6 and 12) as a measure of treatment impact on HF.
REFORM (NCT02397421)
Safety and Effectiveness of SGLT2 Inhibitors in Patients With Heart Failure and Diabetes
• Estimated enrolment: n=56.
• Primary outcome: changes in LV systolic and diastolic volumes in patients as determined by cardiac magnetic resonance imaging.
CV, cardiovascular; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; LV, left ventricular; MI, myocardial infarction; NT-proBNP, N-terminal pro B-type natriuretic peptide; SGLT2, sodium-glucose co-transporter type 2; T2DM, type 2 diabetes mellitus.
indicates a significantly higher risk of adverse outcomes in patients with HF and T2DM, including a higher risk for hospitalization and rehospitalization for HF, as well as increased all-cause and CV mortality, independent of HF aetiology or phenotype (i. 
